Since 2004, AmpliMed has raised a total of $33.1 million which has been used to conduct eight clinical trials involving over 400 cancer patients:

Our current investors include:

The company's efforts are currently concentrated on the clinical development of its lead anti-cancer compound Amplimexon, which is in Phase II clinical trials.

Publications: Concerning Amplimexon® and Amplizone